Literature DB >> 16344831

The role of estrogen therapy in postpartum psychiatric disorders: an update.

Salvatore Gentile1.   

Abstract

OBJECTIVES: The aim of this review is to assess and summarize the existing literature data about the efficacy of estrogen replacement therapy (ERT) in preventing and treating postpartum psychiatric disorders.
METHODS: An extensive and unrestrictive computerized search (from 1970 to June 2005) on MEDLINE/PubMed, TOXNET, EMBASE, and Cochrane Databases was conducted with the following search terms: estradiol, estrogen-treatment, hormonal treatment, therapy, postpartum depression, postnatal depression, puerperal depression, postpartum blues, postpartum psychosis, lactation, and breastfeeding.
RESULTS: In assessing available literature information about the role of ERT in preventing and treating puerperal psychiatric diseases, all reviewed studies were found to suffer from severe methodological limitations.
CONCLUSION: Well-designed and strictly focused multicenter trials are warranted in order to firmly establish the effectiveness of ERT in puerperal psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344831     DOI: 10.1017/s1092852900010518

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  4 in total

1.  Anhedonia in postpartum rats.

Authors:  Brittany M Navarre; Jillian D Laggart; Rebecca M Craft
Journal:  Physiol Behav       Date:  2010-01-12

Review 2.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Using animal models to study post-partum psychiatric disorders.

Authors:  C V Perani; D A Slattery
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  THE NEUROENDOCRINOLOGICAL ASPECTS OF PREGNANCY AND POSTPARTUM DEPRESSION.

Authors:  S Trifu; A Vladuti; A Popescu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.